Description: Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Home Page: alteritytherapeutics.com
350 Collins Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9349 4906
Officers
| Name | Title |
|---|---|
| Mr. Geoffrey Paul Kempler B.Sc. | Co-Founder & Non-Executive Chairman |
| Dr. David A. Stamler M.D. | Chief Executive Officer |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research & Development Advisory Board |
| Dr. Steven D. Targum M.D. | Chief Medical Advisor |
| Dr. Robert Cherny | Head of Research |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4958 |
| Price-to-Sales TTM: | 5.2205 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 10 |